J Hancock Health Sciences A (JHGRX) seeks long-term growth of capital by normally investing at least 80% of its assets in stocks of US and foreign health sciences companies.

The fund may invest in pharmaceuticals and biotechnology companies, medical devices and analytical equipment firms, and healthcare services firms. It may invest more than 5% of assets in securities of individual companies.

The fund’s key holdings include Medco Health Solutions Inc. (MHS), Aetna Inc. (AET) and Abbott Laboratories (ABT).

J Hancock Strategic Income A (JHFIX) seeks a high level of current income. The fund primarily invests in foreign debt securities of developed and emerging markets, U.S. government and agency securities and U.S. high yield bonds.

The fund may also invest in preferred stock and other types of debt securities. At the end of February 2009, its portfolio turnover was 52%.

Daniel S. Janis has been lead manager at the fund since October 1999. The fund has topped total returns of its benchmark index in the last 1-, 3- and 5-year periods.

J Hancock Bond A (JHNBX) was incepted in November 1973. The investment seeks to generate a high level of current income consistent with prudent investment risk.

The fund normally invests in diversified bonds that may include, but are not limited to, corporate bonds and debentures, as well as U.S. government and agency securities. It looks at bonds of all quality levels and maturities from many different issuers.

Unit holders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy”) fund. It has an expense ratio of 1.05%.


Zacks Investment Research